SHOCKER! CRNX Stock: 44% Crash to $10 BILLION Buyout! What Happens NOW?
Can a stock plummet by 44% and then command a stunning $10 billion acquisition just days later? That's precisely what happened to Crinetics Pharmaceuticals. Initially, UBS analysts saw its significant decline as a prime buying opportunity, setting a $55 price target due to a robust pipeline, including a promising Phase 3 program. However, in a dramatic twist, Vertex Pharmaceuticals announced its definitive agreement to acquire Crinetics for an astonishing $85 per share, valuing the company at approximately $10 billion. This acquisition, expected to close by the third quarter of 2026, strategically bolsters Vertex's portfolio with innovative endocrine treatments like PALSONIFY and atumelnant, projecting over $5 billion in potential peak annual revenue. Don't miss out on these incredible market stories; subscribe to our channel for more breaking financial news and insights.
Tags/Hashtags: #crnx #ubs
Leave a Reply